Not finding it? Sign in to also search OpenAlex live.
-
Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Bruno Valentin Sinn, Sibylle Loibl, Claus Alexander Hanusch, Dirk-Michael Zahm, Hans‐Peter Sinn, Michael Untch, +16 more
46citations -
PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?2021 Urologic Oncology Seminars and Original Investigations article Medicine Bladder and Urothelial Cancer Treatments
Gerald Bastian Schulz, Rumyana Todorova, Till A. Braunschweig, Severin Rodler, Yannic Volz, Lennert Eismann, +6 more
14citations -
Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab – the randomized phase 2 FOCUS trial
Anna Paula Brandt, Christoph Schultheiß, Konrad Friedrich Klinghammer, Philippe Schafhausen, Chia‐Jung Busch, Markus Blaurock, +8 more
11citations -
Selektive Kupferchelation reduziert Tumorwachstum und PD-L1-Expression in einem immunkompetenten syngenen Mausmodell des Lungenkarzinoms2026 Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie article Medicine Cancer Immunotherapy and Biomarkers
B. Ohm, S. Andreoli, G. Meier Bürgisser, K Spanaus, Christoph J. Fahrni, W Jungraithmayr, +1 more
0citations -
Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer2021 Journal of Translational Medicine article Medicine PARP inhibition in cancer therapy Open access cited by 1 patent
Jinyu Meng, Jin Peng, Jie Feng, Jochen Maurer, Xiao Li, Yan Li, +11 more
63citations -
UV1 cancer vaccine in pembrolizumab-treated patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma: results from the randomized phase 2 FOCUS trial
Anna Paula Brandt, Konrad Friedrich Klinghammer, Christoph Schultheiß, Lisa Paschold, Claudia Wickenhauser, Marcus Bauer, +17 more
1citations -
9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial
Elena Hartmann, Helen Goergen, Paul Jan Bröckelmann, Anja Mottok, Tabea Steinmüller, Johanna Grund, +10 more
23citations -
Expression of immune checkpoint molecules on adult and neonatal T-cells2022 Immunologic Research article Immunology and Microbiology Immune Cell Function and Interaction Open access
Stefanie Dietz, Kriszta Molnár, Hannah Riedel, Bärbel Spring, Thorsten W Orlikowsky, Christian Friedrich Poets, +2 more
7citations -
OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117)
Viktor Grünwald, Jurgen Alt, Mareike Tometten, Mathias Hänel, Philipp Ivanyi, Gunter Schuch, +7 more
0citations -
Inflammatory signature and restriction of adaptive immunity are associated with unfavorable outcomes on immune checkpoint blockade in patients with advanced head and neck squamous cell carcinoma
Lisa Paschold, Christoph Schultheiß, Paul Schmidt-Barbo, Konrad Friedrich Klinghammer, Dennis Hahn, Mareike Tometten, +8 more
0citations -
Comparative genomic profiling of glandular bladder tumours2020 Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin article Medicine Bladder and Urothelial Cancer Treatments Open access
Angela Maurer, Nadina Ortiz-Bruechle, Karolína Guricová, Michael Rose, Ronja Morsch, Stefan Garczyk, +12 more
44citations